StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Saturday. The firm issued a sell rating on the stock.
Separately, Needham & Company LLC reissued a buy rating and issued a $4.25 target price on shares of OncoCyte in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Hold and a consensus price target of $4.06.
Get Our Latest Stock Analysis on OncoCyte
OncoCyte Trading Up 11.3 %
OncoCyte (NASDAQ:OCX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
See Also
- Five stocks we like better than OncoCyte
- Retail Stocks Investing, Explained
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Election Stocks: How Elections Affect the Stock Market
- MarketBeat Week in Review – 9/16 – 9/20
- 10 Best Airline Stocks to Buy
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.